Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Chemotherapy drug proves effective in fight against pancreatic cancer

  • Comment
A chemotherapy drug after surgery raises the chances of survival for sufferers of the often deadly pancreatic cancer, a study has shown

Pancreatic cancer has a survival rate of only 2% to 3% of patients living five years or more after treatment.

Research from the University of Liverpool found patients given the chemotherapy drug 5FU alongside folinic acid after an operation to remove the cancer had a five-year survival rate of 24%, compared with 14% for those who only had surgery.

The study, published in the British Journal of Cancer and funded by Cancer Research UK, showed that the one-year survival rate for pancreatic cancer has doubled since the 1970s but is still only 13%, dropping further as years pass.

Lead author Professor John Neoptolemos said: "Pancreatic cancer continues to be one of the hardest cancers to treat and has very low survival rates.

"These results show that chemotherapy after surgery is the best way to treat patients, giving people precious extra months or even years of life.

"There is still a long way to go before we can really reduce the number of people that die from the disease but this research moves us in the right direction."

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.